“Three-Dimensional Breast Cancer Spheroids” submitted by radiotherapeutics researcher Debjani Pal is stunning. Brilliant blue dots pop from an electric sphere threaded with bright colors: greens, aqua, hot pink and red.
Four first-of-a-kind 3D-printed fuel assembly brackets, produced at the Department of Energy’s Manufacturing Demonstration Facility at Oak Ridge National Laboratory, have been installed and are now under routine operating
Twenty-seven ORNL researchers Zoomed into 11 middle schools across Tennessee during the annual Engineers Week in February. East Tennessee schools throughout Oak Ridge and Roane, Sevier, Blount and Loudon counties participated, with three West Tennessee schools joining in.
The Transformational Challenge Reactor, or TCR, a microreactor built using 3D printing and other new advanced technologies, could be operational by 2024.
It’s a new type of nuclear reactor core. And the materials that will make it up are novel — products of Oak Ridge National Laboratory’s advanced materials and manufacturing technologies.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
Scientists at the Department of Energy Manufacturing Demonstration Facility at ORNL have their eyes on the prize: the Transformational Challenge Reactor, or TCR, a microreactor built using 3D printing and other new approaches that will be up and running by 2023.
Researchers at the Department of Energy’s Oak Ridge National Laboratory are refining their design of a 3D-printed nuclear reactor core, scaling up the additive manufacturing process necessary to build it, and developing methods
OAK RIDGE, Tenn., Feb. 19, 2020 — The U.S. Department of Energy’s Oak Ridge National Laboratory and the Tennessee Valley Authority have signed a memorandum of understanding to evaluate a new generation of flexible, cost-effective advanced nuclear reactors.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.